Literature DB >> 8585857

EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.

R Uhlmann1, R H Schwinger, I Lues, E Erdmann.   

Abstract

UNLABELLED: The effect of EMD 53998 (EMD) (0.1-100 mumol/l), chemically a racemic thiadiazinone derivative, suggested to be a potent Ca(2+)-sensitizer, was studied in human failing and nonfailing left ventricular myocardium. For comparison, the effects of the pyridazinone derivative pimobendan (0.1-300 mumol/l), isoprenaline (Iso) (0.001-3 mumol/l) as well as CaCl2 (1.8-15 mmol/l Ca2+) were investigated. The positive inotropic responses were examined in electrically driven (1 Hz, 37 degrees C) human left ventricular papillary muscle strips from terminally failing hearts (NYHAIV, n = 24) and nonfailing donor hearts (NF, n = 9). The effect of EMD on the Ca(2+)-sensitivity of skinned fiber preparations from the very same human failing hearts were studied as well. EMD and pimobendan increased force of contraction (FOC) in a concentration-dependent manner. As judged from the EC50-values, EMD increased FOC more potently than pimobendan. EMD was significantly more effective than pimobendan to increase FOC in papillary muscle strips from NYHA IV (EMD: +2.5 +/- 0.1 mN; pimobendan: +0.8 +/- 0.2 mN) as well as from nonfailing hearts (EMD: +3.1 +/- 0.5 mN; pimobendan: +1.2 +/- 0.2 mN). Only in terminally failing myocardium, EMD increased FOC as effectively as Iso. After inotropic stimulation with EMD, pimobendan, or Iso, carbachol (1000 mumol/l) reduced FOC in left ventricular papillary muscle strips, indicating a cAMP-dependent mode of action. In skinned fiber experiments, EMD increased Ca(2+)-sensitivity significantly more (p < 0.01) than pimobendan. IN
CONCLUSION: EMD increases FOC in human myocardium via sensitizing of the contractile proteins towards Ca2+ and by inhibition of phosphodiesterase III-isoenzymes. EMD is a potent calcium sensitizing agent in human myocardium. Thiadiazinone derivatives could be one step in the evolution to more potent and selective calcium-sensitizers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585857     DOI: 10.1007/bf00788497

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  26 in total

1.  Effects of calcium and EMD-53998 on oxygen consumption in isolated canine hearts.

Authors:  P P de Tombe; D Burkhoff; W C Hunter
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

2.  Interaction of DPI 201-106 with cardiac glycosides.

Authors:  G Scholtysik; R Salzmann; W Gerber
Journal:  J Cardiovasc Pharmacol       Date:  1989-02       Impact factor: 3.105

3.  Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.

Authors:  M Ungerer; M Böhm; R H Schwinger; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

4.  Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart.

Authors:  R H Schwinger; M Böhm; J Müller-Ehmsen; R Uhlmann; U Schmidt; A Stäblein; P Uberfuhr; E Kreuzer; B Reichart; H J Eissner
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

Review 5.  Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view.

Authors:  R J Hajjar; J K Gwathmey
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

6.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

7.  Inotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopathy.

Authors:  R H Schwinger; M Böhm; E Erdmann
Journal:  Am Heart J       Date:  1992-01       Impact factor: 4.749

8.  Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure.

Authors:  D J Beuckelmann; M Näbauer; E Erdmann
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

9.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

Authors:  R DiBianco; R Shabetai; W Kostuk; J Moran; R C Schlant; R Wright
Journal:  N Engl J Med       Date:  1989-03-16       Impact factor: 91.245

10.  Evidence against spare or uncoupled beta-adrenoceptors in the human heart.

Authors:  R H Schwinger; M Böhm; E Erdmann
Journal:  Am Heart J       Date:  1990-04       Impact factor: 4.749

View more
  1 in total

Review 1.  Calcium sensitising agents in heart failure.

Authors:  L Mathew; S D Katz
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.